Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Increased Rate of Pulmonary Toxicity in Pediatric Patients with Relapsed Hodgkin Lymphoma Receiving Brentuximab Vedotin

Kelly E Faulk, MD, Jenna Sopfe, MD, Laura Pyle, PhD, Deborah R Liptzin, MD, Arthur K Liu, MD, Anna RK Franklin, MD, Carrye R Cost, MD

Blood (2017) 130 (Supplement 1): 4078.

https://doi.org/10.1182/blood.V130.Suppl_1.4078.4078

Published: 2017

Journal Articles

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Blood (2017) 130 (Supplement 1): 653.

https://doi.org/10.1182/blood.V130.Suppl_1.653.653

Published: 2017

Journal Articles

High-Dose Bendamustine Plus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma

Claudio Cerichione, MD PhD, Maria Di Perna, Novella Pugliese, MD, Novella Pugliese, MD, Roberta Della Pepa, MD, Fabrizio Pane, MD, Marco Picardi

Blood (2017) 130 (Supplement 1): 2802.

https://doi.org/10.1182/blood.V130.Suppl_1.2802.2802

Published: 2017

Journal Articles

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Nitya Gulati, MBBS, Farid Boulad, MD, Maria I. Cancio, MD, Kevin J. Curran, MD, Carolyn Jackson, Nancy Kernan, MD, Andrew L. Kung, MD PhD, Richard O'Reilly, MD, Susan Prockop, MD, Kavitha Ramaswamy, MD, Andromachi Scaradavou, MD, Barbara Spitzer, Neerav Shukla, MD, Peter G. Steinherz, MD, Christopher Forlenza

Blood (2017) 130 (Supplement 1): 5172.

https://doi.org/10.1182/blood.V130.Suppl_1.5172.5172

Published: 2017

Journal Articles

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Quihu Shi, PhD, Jaclyn Basso, RN, MSN, PNP, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4094.

https://doi.org/10.1182/blood.V130.Suppl_1.4094.4094

Published: 2017

Journal Articles

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Blood (2017) 130 (Supplement 1): 4516.

https://doi.org/10.1182/blood.V130.Suppl_1.4516.4516

Published: 2017

Journal Articles

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

Mitchell Braun, BS, Neil Dunavin, MD, Maxwell Pike, MD, Ajoy L. Dias, MD, Tara L. Lin, MD, Leyla Shune, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Anurag K. Singh, MD, Sunil Abhyankar, MD

Blood (2017) 130 (Supplement 1): 5492.

https://doi.org/10.1182/blood.V130.Suppl_1.5492.5492

Published: 2017

Journal Articles

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Vittorio Stefoni, Beatrice Casadei, MD, Barbara Botto, Paolo Corradini, MD, Antonello Pinto, Alessandro Re, MD, Stefania Badiali, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4087.

https://doi.org/10.1182/blood.V130.Suppl_1.4087.4087

Published: 2017

Journal Articles

Low Dose Donor Lymphocyte Infusion (DLI) Is Effective As Prophylactic Therapy for Mixed Chimerism in the Setting of In-Vivo T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Dinesh Atwal, MD, Krishna Joshi, MD, Anusha Jillela, MD, Pooja Motwani, MD, Appalanaidu Sasapu, MD, Muthu Veeraputhiran, MD

Blood (2017) 130 (Supplement 1): 5507.

https://doi.org/10.1182/blood.V130.Suppl_1.5507.5507

Published: 2017

Journal Articles

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Blood (2017) 129 (18): 2471–2478.

https://doi.org/10.1182/blood-2016-11-749556

Published: 2017

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

Journal Articles

Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Bone Marrow Transplantation and Cellular Therapy)

Blood (2016) 128 (22): 3485.

https://doi.org/10.1182/blood.V128.22.3485.3485

Published: 2016

Journal Articles

Everolimus Is Active in Pretreated Hodgkin Lymphoma after Failure of Brentuximab Vedotin: Single Institute Experience

Reyad Dada, Associate Professor, MD, Fawwaz Yassin, MD

Blood (2016) 128 (22): 5368.

https://doi.org/10.1182/blood.V128.22.5368.5368

Published: 2016

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Blood (2016) 128 (22): 4161.

https://doi.org/10.1182/blood.V128.22.4161.4161

Published: 2016

Journal Articles

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Pier Luigi Zinzani, MD PhD, Letizia Gandolfi, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, MD, Enrico Derenzini, MD, Federica Quirini, Lorenzo Tonialini, Michele Cavo, MD, Lisa Argnani, Vittorio Stefoni

Blood (2015) 126 (23): 2725.

https://doi.org/10.1182/blood.V126.23.2725.2725

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

NARROW

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Increased Rate of Pulmonary Toxicity in Pediatric Patients with Relapsed Hodgkin Lymphoma Receiving Brentuximab Vedotin

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

High-Dose Bendamustine Plus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Low Dose Donor Lymphocyte Infusion (DLI) Is Effective As Prophylactic Therapy for Mixed Chimerism in the Setting of In-Vivo T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Bone Marrow Transplantation and Cellular Therapy)

Everolimus Is Active in Pretreated Hodgkin Lymphoma after Failure of Brentuximab Vedotin: Single Institute Experience

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only